ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 77 of 699 for:    BDI | "Depression"

Zinc Supplementation of Imipramine Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00693680
Recruitment Status : Completed
First Posted : June 9, 2008
Last Update Posted : June 13, 2008
Sponsor:
Collaborator:
Jagiellonian University
Information provided by:
Polish Academy of Sciences

Brief Summary:
Examination of the effect of zinc supplementation on imipramine therapy in major depression.

Condition or disease Intervention/treatment Phase
Major Depression Dietary Supplement: Zincas Forte Dietary Supplement: Placebo Not Applicable

Detailed Description:
A placebo-controlled, double blind study of zinc supplementation in imipramine therapy was conducted in sixty, depressed patients fulfilling the DSM-IV criteria for major depression without psychotic symptoms. After a one week washout period, patients were randomized into two groups treated with imipramine and receiving once daily either placebo (n=30) or zinc supplementation (n=30) for 12 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Role of Zinc in Therapy of Unipolar Depression
Study Start Date : January 2005
Actual Primary Completion Date : April 2006
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 1
zinc + imipramine
Dietary Supplement: Zincas Forte
25 mgZn/day + imipramine (100-200mg/day)
Other Names:
  • Zincas Forte (Farmapol, Poland)
  • Imipramin (Polfarma, Poland)

Placebo Comparator: 2
placebo + imipramine
Dietary Supplement: Placebo
placebo + imipramine (100-200mg/day)
Other Name: Imipramin (Polfarma, Poland)




Primary Outcome Measures :
  1. To compare the effect of zinc vs placebo in imipramine treated depressed patients (CGI, BDI, HADRS, MADRS) [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. To assess unwanted side effects in both groups [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with fulfilled DSM-IV criteria for moderate or severe depressive episode
  • one week washout period without any pharmacotherapy

Exclusion Criteria:

  • psychotic symptoms

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00693680


Locations
Poland
Department of Psychiatry, Collegium Medicum, Jagiellonian University
Krakow, Poland, 31-501
Sponsors and Collaborators
Polish Academy of Sciences
Jagiellonian University
Investigators
Principal Investigator: Andrzej Zieba, Prof. Department of Psychiatry, Collegium Medicum

Publications:
Responsible Party: prof. Gabriel Nowak, Institute of Pharmacology, Polish Academy of Sciences
ClinicalTrials.gov Identifier: NCT00693680     History of Changes
Other Study ID Numbers: ZnIMI/2004
First Posted: June 9, 2008    Key Record Dates
Last Update Posted: June 13, 2008
Last Verified: June 2008

Keywords provided by Polish Academy of Sciences:
depression
antidepressant treatment
zinc
placebo

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mood Disorders
Mental Disorders
Zinc
Imipramine
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents